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Abstract
Background: Edible Bird’s Nest (EBN) as a popular traditional Chinese medicine is believed to have health
enhancing and antiviral activities against influenza A virus (IAV); however, the molecular mechanism behind
therapeutic effects of EBN is not well characterized.
Methods: In this study, EBNs that underwent different enzymatic preparation were tested against IAV infected cells.
50% cytotoxic concentration (CC50) and 50% inhibitory concentration (IC50) of the EBNs against IAV strain A/Puerto
Rico/8/1934(H1N1) were determined by HA and MTT assays. Subsequently, the sialic acid content of the used EBNs
were analyzed by fluorometric HPLC. Western Blotting and immunofluorescent staining were used to investigate
the effects of EBNs on early endosomal trafficking and autophagy process of influenza virus.
Results: This study showed that post inoculations of EBNs after enzymatic preparations have the highest efficacy
to inhibit IAV. While CC50 of the tested EBNs ranged from 27.5–32 mg/ml, the IC50 of these compounds ranged
between 2.5–4.9 mg/ml. EBNs could inhibit IAV as efficient as commercial antiviral agents, such as amantadine and
oseltamivir with different mechanisms of action against IAV. The antiviral activity of these EBNs correlated with the
content of N-acetyl neuraminic acid. EBNs could affect early endosomal trafficking of the virus by reducing Rab5
and RhoA GTPase proteins and also reoriented actin cytoskeleton of IAV infected cells. In addition, for the first time
this study showed that EBNs can inhibit intracellular autophagy process of IAV life cycle as evidenced by reduction
of LC3-II and increasing of lysosomal degradation.
Conclusions: The results procured in this study support the potential of EBNs as supplementary medication or
alternative to antiviral agents to inhibit influenza infections. Evidently, EBNs can be a promising antiviral agent;
however, these natural compounds should be screened for their metabolites prior to usage as therapeutic
approach.
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Background
For centuries, influenza epidemics and pandemics have
caused enormous mortality and economical costs for hu-
man and various animal species [1, 2]. As opposed to
the number of attempts to control influenza, currently,
there is no effective control measure to counteract this
devastating disease. Since vaccines only can be available
several months after occurrence of influenza pandemics,
antiviral agents can be considered as the first line of
defense against this virus. However, widespread resist-
ance of influenza A virus (IAV) strains against the
current antiviral agents has emphasized the necessity of
development of new preventive measures [3]. Conse-
quently, scientists started to study several molecular tar-
gets that can be used against influenza viruses, and in a
mean while ameliorate pathogenesis and prognosis of
this disease [3, 4]. Some of these novel targets can be
illustrated by molecular pathways related to influenza
virus entry (e.g. Epsin-1, RTK cascades, Rab5, endosomal
autoantigen 1 (EEA1) and PI3K), and some potential tar-
gets during intracellular autophagy process of influenza
viruses (e.g. mTOR signaling pathways, LC3 and class III
phosphatidylinositol 3-kinase (PI3K) complex) [5, 6].
IAV entry to the host cell is a dynamic action with several
steps that includes attachment of viral hemagglutinin
(HA) with sialic acid receptors of the host cell, internaliza-
tion by receptor-mediated endocytosis (or macropinocyto-
sis), trafficking of endosomes to perinuclear regions,
fusion with endosomal membranes, release of viral ribo-
nucleoprotein complex (vRNP) into the cytoplasm, and
transport of these vRNPinto the host nucleus [5]. After
entry and during the replication, influenza virus would
start to exploit the host autophagy pathway by controlling
of the fusion of lysosomes to the autophagosomes, which
would accelerate the virus replication, reduce antigenicity
of the infected cells to evade the host immune system and
manipulate apoptosis process of the host cells depend on
the state of the infection [6, 7]. Therefore, all of these mo-
lecular pathways can be possible targets for inhibiting IAV
replication and controlling of the disease.
Previous studies have shown that edible bird’s nest
(EBN), a popular Chinese traditional medicine, can in-
hibit the hemagglutination activity of influenza viruses
[8–10]. These nests are mainly produced by two species,
which include white nest swiftlet (Aerodramus fucipho-
gus) and black nest swiftlet (Aerodramus maximus) [11].
This natural medicine composed of more than 78
metabolites from carbohydrates, proteins, fatty acids,
hormones and minerals [12]. This remedy is used for
several purposes like dissolving phlegm, voice improve-
ment, libido raising, gastric problems, renal dysfunc-
tions, asthma, cough and tuberculosis to name but a few
in Chinese medicine and cuisine [13]. In past decades,
scientists have shown many properties of EBNs such as
cell proliferation induction by epidermal growth factor
(EGF) like components, immunomodulatory effects
such as decrease of TNFα and nitric oxide (NO) gener-
ation in RAW cells, improvement of corneal keratocyte
proliferation which can be helpful in wound healing,
neuroprotective activity against 6-hydroxydopamine (6-
OHDA)-induced degeneration of dopaminergic neurons,
improvement of bone strength and skin thickness, chon-
dro protective properties by reduction of catabolic activ-
ities and potential antiviral activity against influenza
viruses [8, 10, 14–18]. Despite of these studies, potential
bioactivities of EBN’s components require subsequent
researches and characterization of the mechanisms of
action that can provide valuable information on their
usage in orthodox medicine.
Consequently, the current study was designed to evalu-
ate the antiviral properties of EBN against two of the
aforementioned molecular pathways in IAV life cycle. At
first, the cytotoxic and antiviral activity of EBNs with dif-
ferent enzymatic treatments against IAV was determined.
Later, this study focused on the effects of EBN on early
endosomal trafficking of IAV by evaluating actin cytoskel-
eton and small GTPAse proteins such as Rab5 as early
endosomes biomarker and RhoA that involve in actin fila-
ments polymerization. Finally, intracellular autophagy
process was assessed by LC3-II protein as a marker for
autophagosomes accumulation and immunoflourescent
staining of lysosomes for lysosome activity.
Methods
Reagents and chemicals
The materials of this study were purchased from differ-
ent sources as follows: Dulbecco’s modified Eagle’s
medium (DMEM) and penicillin-streptomycin solution
from Mediatech Cellgro Company (Northbrook, Illinois,
USA), Accutase® cell detachment solution from Innova-
tive Cell Technologies (San Diego, California, USA), fetal
bovine serum (FBS) from PAA Laboratories (Pasching,
Austria). Plastic wares (Orange Scientific, Braine-
l’Alleud, Belgium), Lab-Tek II Chamber Slides (8-well)
(Thermo scientific, New York, USA) were used during
the experiments. Amantadine hydrochloride, oseltamivir
carboxylate, Tosylamide phenylethyl chloromethyl keton-
treated trypsin (TPCK-Trypsin), 3-(4, 5-dimethyl-2-thiazo-
lyl)-2, 5- diphenyl-2H-tetrazolium bromide (MTT), fluor-
escent rhodamine 110 phalloidin, RhoA inhibitor,Y-27632
dihydrochloride and lysosome inhibitor,Bafilomycin A1
(BafA1) were procured from Sigma (Saint Louis, Missouri,
USA). Rab5 inhibitor, NE10790was provided by Dr. David
F. Wiemer, Department of Chemistry, University of Iowa,
USA. Pancreatin F and neuraminidase were purchased
from Sigma, USA. ProLong® Gold Antifade reagent and
LysoTracker Red DND-99 were obtained from Invitrogen
(Carlsbad, California, USA).
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Protein extraction kit (ab65400), rabbit polyclonal anti-
Rab5 antibody (ab18211), rabbit polyclonal anti-RhoA anti-
body (ab68826), rabbit polyclonal anti-LC3A/B antibody
(ab58610), mouse monoclonal anti-pan cadherin antibody
[CH-19] (ab6528) and goat polyclonal anti-mouse IgG
H&L (alkaline phosphate conjugated) (ab97020) were pro-
cured from Abcam (Cambridge, USA).
Virus and cell culture
Influenza virus strain used in this study, A/Puerto Rico/
8/1934 (H1N1) (ATCC VR-1469™), and Madin Darby
Canine Kidney (MDCK) cell line (CCL-34™) were ac-
quired from ATCC. The viral stocks were propagated in
MDCK cells in the presence of 0.5 μg/ml of TPCK-
Trypsin. DMEM containing 10% heat-inactivated FBS,
100 units/ml penicillin G and 100 μg/ml streptomycin
was used as growing media. Incubation conditions were
37 °C with 5% CO2. DMEM supplemented with TPCK-
Trypsin (0.5 μg/ml) was used as maintenance media
during antiviral experiments. During virus-stock prepar-
ation, virus infected MDCK cells at three days post-
infection were used. Tissue culture infectious dose 50
(TCID50) in combination with hemagglutination assay
were used to measure virus infectivity dose in different
treatments [19, 20].
Preparation of EBN extracts
EBN extracts were prepared based on enzymatic and
heat treatments as described in a previous study with
some modification [8]. House nest EBN from Teluk
Intan, Perak, Malaysia and cave nest EBN from Gua
Madai caves, Lahad Datu, Sabah, Malaysia were collected
by our research team (Dr. Kadir and Dr. Mehrbod) and
formally identified by Dr. Fadzilah A’ini, Kadir.A (Chair-
man of ranching Edible-Nest Swiftlet, Malaysia Standards
(MS)). The collected EBNs were prepared in four types as
follows: 1) House nest EBN from Teluk Intan of Perak,
Malaysia, with no enzymatic treatment, 2) House nest
EBN from TelukIntan of Perak, Malaysia, with pancreatin
F-treatment, 3) Cave nest EBN from Gua Madai of Sabah,
Malaysia, with no enzymatic treatment, 4) Cave nest EBN
from Gua Madai of Sabah, Malaysia, with neuraminidase-
treatment. For preparation, first, nests were dried at 70 °C
for 16 h. Afterwards, they were grounded and filtered with
600 μm in pore size mesh to remove the feathers and for-
eign substances. Later, 5 g of each sample were suspended
in 200 ml dH2O for 16 h at 5°Cfollowed by heating for
around 1 h at 60 °C. Afterwards some of the samples were
treated with 0.5 mg/ml of pancreatin F for 4 h at 45 °C
with pH 8.5–9.0. Subsequently, suspensions were heated
at 90 °C for 5 min for enzyme deactivation. The treated
extracts were filtered using filter papers (ADVANTEC
filter paper no. 2) and after 48 h freezing at −80 °C the
filtrate was freeze-dried, and then stored at −80 °C for
further use. Samples that were treated with neuramin-
idase (from Clostridium perfringens) (N2876, Sigma)
also followed the same process except for the incuba-
tion at 37 °C for 2 h. A working concentration of
0.05 g/ml of dH2O was used for cell culture exposure.
Hemagglutination-inhibitione test
Briefly, EBNs were two-fold serially diluted in round-
bottomed wells in 96-well microtitre plates (Nunc,
Denmark). From the virus stock, 4HA unit (the lowest
amount of virus particles able to agglutinate the chicken
erythrocytes) was added to all wells (25 μl/well) to inves-
tigate the inhibitory effect of EBNs onto the hemaggluti-
nating activity. After pre-incubation of 45 min at room
temperature (R.T.), chicken erythrocytes (taken from
chicken, washed with PBS at least 3 times and diluted
to 1%) were mixed with the solution. Following 1 h
incubation at R.T. the agglutination inhibition pattern
was read.
Cytotoxicity evaluation of EBNs
To determine possible cytotoxic effects of EBN extracts,
monolayer MDCK cells in 96-well plates were exposed
to different concentrations of EBN for 48 h with at least
six replications and cell viability was measured by
methylthiazolyl- diphenyl-tetrazolium bromide (MTT)
viability assay as described by Mehrbod et al. [20].
Briefly, cell monolayers were washed after 48 h exposure
period and 100 μl MTT 1X in Phosphate buffered saline
(PBS) was added to each well and the plates were further
incubated at 37 °C in CO2 incubator for 2–3 h.
Solubilization of the formed formazan crystals during
this period was achieved by the addition of DMSO
solution. Color adsorption (OD) was evaluated by mi-
croplate reader (BioTek EL 800, US) at 570 nm. Cell
survival rate was determined as average OD of treat-
ment value/average OD of control value. Accordingly,
the 50% cytotoxic concentration (CC50) causing cyto-
pathic effects in half of the cells as a ratio to control
cell and maximum non-cytotoxic concentration
(MNCC) of EBNs were determined.
EBN extracts antiviral activity
For antiviral assessment of EBNs, semi-confluent mono-
layer MDCK cells in 96-well plates were exposed to EBN
extracts (MNCC) and IAV (100 TCID50/0.1 ml) in three
different exposure types. Briefly, MDCK cells were
treated with EBNs for 1 h, which were followed by 1 h
incubation with virus for infection (pre-treatment assay),
adding EBNs and viruses together to the monolayer cells
with 1 h incubation period (co-treatment assay), or treat-
ment of already infected cells with EBNs for 1 h period
(post-treatment assay). Afterwards, cells were covered
with medium containing TPCK-Trypsin (0.5 μg/ml) for
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48 h. Subsequently, the viability of the cells was defined
by MTT assay and virus titers were determined by
hemagglutination assay [21]. During all antiviral activity
tests, cell viability and viral load of non-treated cells and
non-infected cells treated with EBNs or antiviral agents
were considered as the negative controls for comparison
and reliability confirmation of each experiment. Later,
percentage of protection of each treatment was calcu-
lated by the following formula:
Percentage of protection ¼ A−B
C−B
A: Absorbance of the samples
B: Absorbance of the virus-infected control
C: Absorbance of negative control of both virus and
compound
Since the results showed that post-treatment of IAV
with EBNs had the highest protection, this treatment
approach is further analyzed by incubating the infected
cells with EBNs for 1, 8 & 24 h. The cell viability and
virus titers were determined at 48 h post infection time
point by MTT and HA assays. In the last step, 50% in-
hibitory concentration (IC50) of EBNs were determined
by treating the infected cells with serial dilution of each
EBN, followed by HA assay for determination of virus
inhibition in each treatment. Later, the selectivity index
(therapeutic index) of each EBN was calculated as a ratio
of CC50/IC50 for each compound.
Fluorometric HPLC analysis of EBNs for sialic acid contents
In this step, total 5-N-acetylneuraminic acid (Neu5Ac)
contents of the prepared EBNs from Gua Madai and
Teluk Intan with no enzymatic treatments were analyzed
by fluorometric high performance liquid chromatog-
raphy (HPLC) as described previously [22]. Briefly, 5 mg
of samples were solved in sodium hydrogen sulphate so-
lution and incubated at 80 °C for 30 min. Afterwards,
the sialic acids were derivetized by o-Phenylenediamine
dihydrochloride (Sigma, USA) and separated on a C18
column by a mobile phase composed of 1.0% tetrahydro-
furan aqueous and acetonitrile at 1.0 ml/min flow rate in
an isocratic elution. The fluorescent intensities were
analyzed at 230 nm excitation and 425 emission wave-
lengths. Finally, sialic acids were identified and quanti-
fied using the elution position and standard curve of
Neu5Ac standard (Sigma, USA).
Sample preparation for immunoblotting
For this step, MDCK cells were cultured in the required
number in 75 cm2 flasks (Orange Scientific, Belgium) for
different treatments. Then, the infected (100 TCID50/
0.1 ml) and non-infected semi confluent flasks were
treated with EBNs or anti-influenza drugs as described
above. After 48 h incubation, the cells were scraped, col-
lected in chilled PBS and centrifuged to form pellet. Then,
the cell pellets were suspended in 1 ml of cytobuster™ pro-
tein extraction reagent (Novagen, USA) containing 2%
protease inhibitor cocktail from Protein extraction kit
(ab65400) (Abcam, UK). After vortexing with beads for
few minutes, the lysates were centrifuged for 3 min at
825 × g. 4 °C. The supernatants were transferred to new
microtubes and stored at −80 °C till further usage. The
concentration of the proteins of the samples were assessed
by Bradford assay [23] and all the concentrations were
normalized to 1 μg/μl by dilution with PBS.
Detection of Rab5, RhoA and LC3 translocation in
MDCK cells
For Western blotting, 1 μg of proteins of each sample
was fractionized by sodium dodecyl sulfate polyacryl-
amide gel electrophoresis (SDS-PAGE) and electrophor-
etic transfer of the bonds to nitrocellulose membrane
(Bio-Rad, USA) using vertical semi-dry electroblotting.
Subsequently, the membranes were blocked by milk di-
luent as blocking buffer (Kierkegaard and Perry Labora-
tories, Gaithersburg, USA) for 1 h at room temperature.
Then, the membranes were washed for three times with
Tris Buffered Saline (TBS)-tween buffer, which followed
by incubation with specific primary antibody at 4 °C
overnight. In the next day, the membranes were washed
for few times and incubated with alkaline phosphatase-
conjugated antibody at room temperature for 1 h. This
was followed by three times washing and visualizing of
the bands by enzymatic reaction with BCIP-NBT substrate
(Sigma, USA). Subsequently, the bands were scanned with
Odyssey infrared imaging system (Li-COR Bioscience,
Nebraska, USA) at 21–339 μm scanning range. The inten-
sity of the bands was quantified on a single channel. Pan-
Cadherin protein was used as house-keeping protein to
normalize the result of each sample.
Immunofluorescent labelling of actin cytoskeleton and
lysosomal bodies
MDCK cells cultured up to 80% confluent in 8-well
chamber-slides (8 × 104 cell/well) for 24 h. Then, influ-
enza infected (100 TCID50/0.1 ml) or non-infected cells
were treated with EBN extracts as described above. For
visualization of actin cytoskeleton, the cells were fixed
by fresh 3% paraformaldehyde in PBS for 10 min at 4 °C
at the end of the incubation period of 24 h. This was
followed by permeabilization with 0.2% Triton-X-100 at
room temperature, washing with PBS and then blocking
with 10% FBS in PBS for 1 h at 4 °C. Finally, rhodamine
110 phalloidin stain with 2 μM concentration (1:50 dilu-
tion in blocking buffer) were used for 20 min at room
temperature to label the cells. For detection of lysosome,
the live treated cells were incubated with pre-warmed
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media containing 50 nM LysoTracker Red DND-99 for
25 min at 24 h post infection time point, which was
followed by fixation with 3% paraformaldehyde as be-
fore. At the end, all the labeled slides was mounted with
warm anti-fade reagent containing 4′,6-diamidino-2-
phenylindole (DAPI) (1 μg/ml) as nuclear counter-stain
and sealed with nail polish. Fluorescent images were ac-
quired using confocal microscopy (Olympus, Japan)
using suitable filters (502 nm excitation and 524 nm
emission for rhodamine 110 phalloidin, 577 nm excita-
tion and 592 nm emission for LysoTracker, and 358 nm
excitation and 461 nm emission for DAPI) on 100X lens,
0.164 μm pixel resolution, and scanning at speed of 5
with averaging of four lines from an argon–krypton
laser. The images were processed using Flouview ver3.1a
and ImageJ64 software.
Statistical analysis
Data statistical analyses, which were expressed as mean
± SD, were performed using Statistical Package for the
Social Sciences (SPSS 22.0). One-way analysis of vari-
ance (ANOVA) post-hoc Dunkan test were used to
evaluate the significance of differences (p < 0.05) among
treatments. For the data with two continuous variables,
like CC50 and IC50 determination, linear regression was
used to calculate these values by respective prediction
formulas. Lastly, the graphs with the respective analysis
were drawn by Graphpad Prism version 5.0 software.
Results
Cytotoxicity results
As shown in Table 1, EBNs from Teluk Intan showed
lower CC50 (27.5–30.5 mg/ml) in contrast to the ones
from Gua Madai (31.5–32 mg/ml). Both enzymatic treat-
ments increased the CC50 concentration of the treated
EBN; however, pancreatin F decreased the toxic effects
of EBN more efficiently. The highest concentration with
no significant cytotoxicity, which was considered as
MNCC of EBNs for following experiments, was
12.5 mg/ml in all EBNs (Table 1). CC50 of amantadine in
MDCK cells was 4523.4 mg/ml, which is equal to
24.09 mol/L. This value was 14373.2 mg/ml (35.02 mol/L)
for oseltamivir in MDCK cells. The results showed that
1510.0 mg/ml (8.04 mol/L) of amantadine and 3120.0 mg/
ml (7.60 mol/L) of oseltamivir is the highest concentra-
tions with no cytotoxicity for MDCK cells, which were
used as MNCC of these drugs in the following steps.
Hemagglutination-inhibition results
Untreated erythrocytes were precipitated to the bottom of
the wells, while upon pre-incubation with virus the blood
cells showed even and diffuse distribution. EBN dilutions
did not inhibit RBC agglutination at all, arguing against
physical interaction of the EBN ingredients with RBC.
Treatment of influenza virus with EBN reduced the hea-
magglutination activity of the virus, which indicates phys-
ical interaction of EBNs with virus hemagglutinin up to a
certain dilution (dose-dependent manner).
EBN extracts inhibitory effect on influenza A virus
The results of both HA and MTT assays for antiviral ac-
tivity of EBNs against IAV showed that post treatment of
influenza with EBN significantly (p < 0.05) reduced the
virus titer and increased the cell viability (Table 2).
While all the EBN samples showed significant antiviral
activity, the EBN from Gua Madai with no enzymatic
treatment (EBN3) showed the highest antiviral activity
by reducing the virus HA titer from 1:128 to 1:10–1:20.
In addition, the results showed that pancreatin F could
not increase the antiviral activity of EBN. However,
neuraminidase treatment of EBNs reduced the antiviral
activity by increasing the virus HA titer from 1:10 to
1:20 and decreasing the percentage of protection of
these compounds from 61 to 54% (Table 2). As opposed
to the effects of EBNs, co-inoculation of amantadine and
oseltamivir showed the highest efficiency by reduction of
1:128 virus HA titer to 1:5–1:10 (Table 2). Regarding the
percentage of protection, EBN3 had the highest protec-
tion compared to the other EBNs. The results revealed
that post-inoculation of EBN from Gua Madai with no
enzymatic treatment (EBN3) could protect more than
60% of the infected cells compared to other EBNs (42 to
53% of protection), amantadine (39% of protection) and
oseltamivir (40% of protection) (Table 2).
This study also showed that increasing the post treat-
ment period of EBNs would significantly (p < 0.05) aug-
ment the antiviral activity of these compounds (Fig. 1).
At 48 h post infection, the HA results showed that 24 h
treatment of IAV (1:256 HA titer) with EBN can signifi-
cantly (p < 0.05) reduce the HA titer from 1:32 to 1:11 in
comparison with 1 h or 8 h EBN treatment durations. In
contrast to HA titer, the viability of the cells did not sig-
nificant changed with different treatment durations. In
addition to EBNs, the results showed that 24 h treat-
ment of infected cells with oseltamivir also significantly
(p < 0.05) improved the antiviral activity of this com-
pound. Since EBNs showed higher efficacy in this time
Table 1 CC50, IC50 and selectivity index of different EBN sources
and enzymatic treatments
EBN1 EBN2 EBN3 EBN4
CC50 (mg/ml) 27.5 30.5 31.5 32
IC50 (mg/ml) 4.9 3.6 2.5 3.6
Selectivity index 5.61 8.47 12.60 8.89
EBN1 EBN from Teluk Intan with no enzymatic treatment, EBN2 EBN from Teluk
Intan with Pancreatin F treatment, EBN3 EBN from Gua Madai with no enzymatic
treatment, EBN4 EBN from Gua Madai with neuraminidase treatment
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point, 24 h treatment duration was chosen for the
following steps of this study.
IC50 and selectivity index results
Linear regression analysis of the HA results for IC50 de-
termination showed that the IC50 of the EBNs ranged
from 2.5–4.9 mg/ml. In the next step, the therapeutic
(selectivity) index of the EBNs was calculated from the
ratio of CC50 per IC50. The results showed that the
EBN extract from Gua Madai with no enzymatic treat-
ment (EBN3) has the highest selectivity index (12.6)
compared to other EBNs. In general, EBNs from Gua
Madai had lower IC50 (2.5–3.6 mg/ml) and higher
selectivity index (8.89–12.6) than EBNs from Teluk
Intan (Table 1). Meanwhile, pancreatin F treatment of
EBN increased the selectivity index from 5.6 to 8.5,
while neuraminidase treatment decreased this value
from 12.6 to 8.9.
Sialic acid contents of EBNs
HPLC analysis of the standard revealed that Neu5Ac
would be released after around 20 min. Hence, following
analysis of EBNs from Teluk Intan and Gua Madai
showed that both EBN samples contain Neu5Ac with
different concentrations. According to HPLC results,
EBN from Gua Madai contained 6.7 mg/g of Neu5Ac,
which was higher than 3.2 mg/gr in EBN from Teluk
Intan. Figure 2 shows the chromatograms of fluoromet-
ric HPLC analysis of sialic acid in standard and both
EBNs of this study.
Table 2 Antiviral effects of EBNs and anti-influenza drugs on IAV infected MDCK cells




Percentage of protection (%)
(Mean ± SD)
Co inoculation E1 + PR 0.58 ± 0.17 6 ± 0 31.52 ± 24.81abcd
E2 + PR 0.55 ± 0.1 6.67 ± 0.58 27.98 ± 14.62abc
E3 + PR 0.59 ± 0.13 6.33 ± 0.58 33 ± 18.79abcd
E4 + PR 0.53 ± 0.07 6.33 ± 0.58 22.65 ± 9.11abc
AMA + PR 0.64 ± 0.01 3.33 ± 0.58* 39.9 ± 1.71abcde
OSE + PR 0.63 ± 0.05 2.33 ± 0.58* 39.41 ± 8.14abcde
Pre inoculation E1 + PR 0.53 ± 0.07 6.33 ± 0.58 24.72 ± 10.06abc
E2 + PR 0.54 ± 0.06 6.67 ± 0.58 26.2 ± 8.97abc
E3 + PR 0.61 ± 0.05 6.33 ± 0.58 35.66 ± 7.99abcd
E4 + PR 0.65 ± 0.04* 6.33 ± 0.58 42.17 ± 5.67bcde
AMA + PR 0.5 ± 0.06 6.33 ± 0.58 20.19 ± 8.41ab
OSE + PR 0.52 ± 0.03 5.33 ± 0.58* 22.16 ± 5.19ab
Post inoculation E1 + PR 0.66 ± 0.05* 5 ± 0* 42.47 ± 8bcde
E2 + PR 0.67 ± 0.06* 5 ± 0* 45.42 ± 8.4cde
E3 + PR 0.78 ± 0.19* 3.33 ± 0.58* 61.1 ± 27.4e
E4 + PR 0.73 ± 0.10* 4.33 ± 0.58* 53.7 ± 15.54de
AMA + PR 0.5 ± 0.07 6.33 ± 0.58 20.19 ± 10.9ab
OSE + PR 0.52 ± 0.03 6.33 ± 0.58 18.71 ± 6.67a
Controls PR (Control) 0.37 ± 0.19 7 ± 0
Negative control 1.04 ± 0.09*
EBN1 with no virus 0.8 ± 0.14*
EBN2 with no virus 0.81 ± 0.03*
EBN3 with no virus 0.87 ± 0.10*
EBN4 with no virus 0.8 ± 0.14*
Ama with no virus 0.86 ± 0.04*
Ose with no virus 0.89 ± 0.00*
Note: The results are average of at least 6 replicates for each group
E1 EBN from Teluk Intan with no enzymatic treatment, E2 EBN from Teluk Intan with Pancreatin F treatment, E3 EBN from Gua Madai with no enzymatic
treatment, E4 EBN from Gua Madai with neuraminidase treatment, Ama Amantadine hydrochloride, Ose Oseltamivir carboxylate, PR influenza A virus,
A/Puerto Rico/8/1934(H1N1)
*Shows significant difference with infected control (PR) (p < 0.05). Different letters on the top of the percentage of protection data show the statistical grouping
by Duncan analysis of the treatments (p < 0.05)
Haghani et al. BMC Complementary and Alternative Medicine  (2017) 17:22 Page 6 of 13
Modulation of the Rab5 protein
Evaluation of Rab5 as a marker for early endosomes re-
vealed that infection of MDCK cells with IAV caused
significant (p < 0.05) increase in intracellular Rab5. All
EBNs could significantly (p < 0.05) affect the endocytosis
of the virus by decreasing of this protein (Fig. 3). How-
ever, the EBNs from Teluk Intan (EBN1 and EBN2)
showed more efficiency compared to the ones from Gua
Madai (EBN3 and EBN4). Regarding the enzymatic
treatments, this study showed that the EBN with pan-
creatin F treatment (EBN2) had significant (p < 0.05)
higher level of Rab5 in both infected and non-infected
cells in comparison with EBN with no enzymatic treat-
ment (EBN1). On the other hand, EBN with neuraminid-
ase treatment (EBN4) showed significant (p < 0.05) lower
level of Rab5 in only infected cells compared to EBN
with no treatment (EBN3). In general, EBN extracts were
more effective in reducing Rab5 than Rab5 inhibitor
NE10790 (Fig. 3). Among the anti-influenza drugs,
oseltamivir was also effective against the early endo-
somes trafficking and significantly (p < 0.05) decreased
the amount of Rab5 in infected cells. This drug
caused significant (p < 0.05) increase in Rab5 in the
normal cells. In contrast to oseltamivir, amantadine
did not affect Rab5 protein of neither infected nor
normal cells (Fig. 3).
Modulation of the RhoA protein
This study showed that IAV significantly (p < 0.05) in-
creased the RhoA protein compared to the negative con-
trol. On the other hand, the results revealed that EBNs
significantly (p < 0.05) decreased the RhoA in both pres-
ence and absence of the virus (Fig. 3). No significant
difference was detected among different types of EBNs.
Both EBNs from Gua Madai and Teluk Intan showed
similar effects on RhoA protein in infected and non-
infected cells. In addition, both enzymatic treated and
untreated EBNs also reduced RhoA protein with no
significant differences. Although treatment with the
control drugs decreased RhoA, the treatments were
not as effective as EBNs in reduction of this protein.
The level of RhoA in amantadine and oseltamivir was
significantly higher in both infected and non-infected
cells in comparison with EBNs. These drugs could
maintain the RhoA protein as the negative control
level and only oseltamivir slightly reduced the RhoA
level in normal cells. In addition, EBNs could signifi-
cantly (p < 0.05) reduce RhoA protein more than Y-
27632the control inhibitor of RhoA.
Immunoblotting for LC3 localization
After analysis of LC3-II protein as the marker of autop-
hagosomes, the results showed that EBNs significantly
(p < 0.05) reduced the LC3-II protein in presence of
the virus. EBNs from Teluk Intan showed significantly
(p < 0.05) higher efficiency in reducing LC3-II protein
level than the ones from Gua Madai (Fig. 3). However,
pancreatin F treatment of EBN did not change this prop-
erty of EBN in reducing of LC3-II protein. On the other
hand, the EBN with neuraminidase treatment (EBN4)
failed to reduce LC3-II protein in neither infected nor
non-infected cells. In contrast to EBNs, oseltamivir signifi-
cantly (p < 0.05) increased the amount of LC3-II protein
in both infected and non-infected cells. Amantadine did
not affect LC3-II protein in infected cells. However, this
drug significantly (p < 0.05) increased the level of LC3-II
protein in normal cells. BafA1 was used as the control
inhibitor of the lysosome activity. Inhibition of the
Fig. 1 Effects of post-inoculation of EBNs at different incubation periods against IAV. a Statistical analysis of HA assay results at 48 hpi of the trend
of antiviral activity of EBNs with different inoculation periods. Ose was tested as antiviral control drug. b The trend of change in virus titer at 48
hpi following different post infection inoculation of EBN. Alphabets show the significant (p < 0.05) differences among different treatments. E1: EBN
from Teluk Intan with no enzymatic treatment, E2: EBN from Teluk Intan with Pancreatin F treatment, E3: EBN from Gua Madai with no enzymatic
treatment, E4: EBN from Gua Madai with neuraminidase treatment, Ose: Oseltamivir carboxylate, PR: influenza A virus (A/Puerto Rico/8/1934
(H1N1)). The statistical method ANOVA and post hoc Duncan was used to analyze the significant difference (p < 0.05)
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lysosomes with this pharmacological inhibitor significantly
increased the amount of LC3-II protein and autophago-
somes (Fig. 3).
Actin cytoskeleton organization alterations
Immunofluorescent staining of the actin filaments in dif-
ferent treatments revealed that EBNs could reorient and
normalize the actin filaments dissociation following virus
infection. Apparently, IAV infection of the MDCK cells
increased the actin stress fibers and impaired cytoskel-
eton filaments. As shown in Fig. 4, IAV increased the
density of the actin filaments and change the shape of
the cells. Treatment of infected cells with EBNs helped
normalizing the cellular shapes and also reorienting the
actin filaments (Fig. 4). In addition, the densities of actin
filaments seem to be reduced by EBNs. In the absence of
the virus, EBNs did not show any particular effect on
the actin filaments.
LysoTracker red staining analysis
Figure 5 shows the differences of intracellular lysosomal
activityand the number of lysosomal bodies in normal
and infected cells after treatments with different EBNs.
IAV infection slightly increased the number of lysosomal
bodies in comparison with the negative control. The re-
sults revealed that upon the treatment of both non-
infected and infected cells with EBNs, the density and
the number of lysosomes increased. While, most of the
EBNs with different enzymatic treatments showed simi-
lar effects in increasing of lysosomal compartments,
neuraminidase treatment of EBN seemed to slightly re-
duce this property of EBN in augmenting intracellular
lysosomal activity (Fig. 5).
Discussion
The results of our study showed that EBNs can act as ef-
fective as common antiviral agents against influenza virus
albeit with distinct mechanism of action. In addition,
some EBNs showed better efficacy and protective percent-
age against this virus than these drugs. While amantadine
and oseltamivir had the highest efficacy when inoculated
simultaneously with the virus, post inoculation of the
EBNs after virus infection had the highest antiviral activity
and percentage of protection against IAV. Hence, these re-
sults might indicate the mechanism of action of EBNs is
not related to virus attachment to the host cell, but it
might be relevant to its release process from the cell
membrane. It is worth mentioning that this is the first
study that investigates the antiviral activity of EBNs with
different exposure methods.
In this study, EBNs originated from two different loca-
tions in Malaysia (Teluk Intan and Gua Madai) was
treated with pancreatin F or neuraminidase during prep-
aration. Regardless of enzymatic treatment, our results
support the fact that depends on the origin, EBNs’ bio-
activity can significantly change. Accordingly, the EBN
from Gua Madai showed higher antiviral activity com-
pared to the ones from Teluk Intan. Recently, Chua and
his colleagues analyzed the metabolomics profiles of 152
EBNs with different origins and characteristics [12]. This
study indicated that EBNs from different countries, col-
oration and production sites have significant variations
in their metabolite compositions [12]. Previous studies
also has shown that most of the proteins of the EBN is
conjugated with different glycans such as O-glycans,
Fig. 2 Fluorometric HPLC analysis of sialic acids in EBNs from Gua
Madai and Teluk Intan. The chromatograms show the release of
Neu5Ac with around 20 min retention time in a standard, b EBN
from Gua Madai, and c EBN from Teluk Intan
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glycosaminoglycans and N-glycans, particularly α2,3-
N-acetylneuraminic acids (sialic acids) [24], which are
able to inhibit the hemagglutination activity of differ-
ent strains of influenza A viruses [8]. Hence, in this
study we evaluated the Neu5Ac contents of our EBN
samples. Apparently, the concentration of this sialic
acid is correlated with antiviral activity of EBN
against influenza, which caused higher potency of
EBN from Gua Madai compared to the one from
Teluk Intan. Hence, before introducing of this natural
product as an antiviral agent, it is necessary to understand
the mechanism of action and the metabolomics compos-
ition of the EBNs.
Two different enzymatic treatments were used in this
study to elucidate the possible groups of active com-
pounds in EBN against influenza virus. Pancreatin is a
mixture of digestive enzymes that are secreted from pan-
creas with proteolytic, amylolytic and lipolytic activities.
Previous studies showed that treatment of EBNs with
this enzyme significantly increase the protein solubility,
the degree of hydrolysis and bioactivepeptides concen-
tration of the mixture [25]. In this study, the pancreatin
Fig. 3 Effects of EBNs on Rab5 (a), RhoA (b), and LC3-II (c) proteins along with the acquired bands in the SDS-PAGE analysis. Alphabets show the
Duncan analysis of the differences among the groups. * indicates the significant difference (p < 0.05) from the positive infected control (PR). E1:
EBN from Teluk Intan with no enzymatic treatment, E2: EBN from Teluk Intan with Pancreatin F treatment, E3: EBN from Gua Madai with no enzymatic
treatment, E4: EBN from Gua Madai with neuraminidase treatment, Ama: Amantadine hydrochloride, Ose: Oseltamivir carboxylate, PR: influenza A virus,
A/Puerto Rico/8/1934 (H1N1)
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F treatment of the Teluk Intan EBN significantly in-
creased the antiviral activity of EBN. This result was not
as predominant of previous study on the effects of pan-
creatin F treated EBN against influenza viruses [8],
which might be the result of composition variation of
EBNs used in these studies. Most likely, the EBN from
Teluk Intan in our study has other active compounds in
addition to amino acids or glycan residues, which are
not affected by pancreatin F enzyme.
The other enzyme that was used in this study was
neuraminidase. This is a glycoside hydrolysis enzyme
that splits the glycosidic linkages of sialic acids [26]. As
described before, sialic acids are one of the main compo-
nents of EBN that correlate with antiviral activity of
EBN. Hence, neuraminidase treatment of EBN can show
the possibility of existence of other bioactive compounds
in EBN against IAV. The results of our study also sup-
port the sialylglycoconjugates against IAV; however, even
with neuraminidase treatment, EBNs still showed effi-
cient antiviral activity in lower levels. Consequently, in
addition to sialic acid residues, other bioactive com-
pounds might inhibit influenza virus with direct or indir-
ect mechanism of action. Recently, GC/MS and LC/MS
metabolomic profiles of EBNs revealed that there are
more than 78 metabolites belong to a wide range of
chemical classes like organic acids, amino acids, sugar,
sugar alcohol, fatty acid amides and steroids [12] with
potential antiviral and antimicrobial activities. More
Fig. 4 Reorientation of actin cytoskeleton in infected MDCK cells after treatment with EBNs detected by rhodamine 110 phalloidin staining. EBN1:
EBN from Teluk Intan with no enzymatic treatment, EBN2: EBN from Teluk Intan with Pancreatin F treatment, EBN3: EBN from Gua Madai with no
enzymatic treatment, EBN4: EBN from Gua Madai with neuraminidase treatment, Ama: Amantadine hydrochloride, Ose: Oseltamivir carboxylate,
PR: influenza A virus, A/Puerto Rico/8/1934 (H1N1). The control staining shows the normal appearance of the actin filaments. The PR image shows
the alteration of actin filaments in MDCK cells after infection with 100 TCID50/ml of the virus. The other images demonstrated the effects of EBNs
in presence and absence of the virus. Bar: 20 μm. All images were taken at 100X oil immersion lens. The arrows show the actin filaments
in each treatment
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studies are required to elucidate the effects of this com-
pound against influenza virus.
During the influenza life cycle, this virus overcomes
several barriers and manipulates the host cellular com-
partments to replicate and hide from the immune
system. The endosomal system and the following au-
tophagy process are two of the natural cellular pathways
that are widely harnessed by influenza virus for its own
benefits. After endocytosis or macropinocytosis of IAV
inside the cell, the virus exploits these systems by inhi-
biting the endosomal maturation and changing in pH to
release the vRNP into the cytoplasm for replication.
While the virus inhibits the lysosomal degradation of the
late endosomes and formation of the autolysosomes, it
induces the formation of the autophagosomes to acceler-
ate the replication and manipulate the host immune
responses [6]. The virus also can trigger the autophagic
cell death or regulate the apoptosis by maneuvering the
autophagic system [27, 28]. Hence, inhibiting or interfer-
ing with these mechanisms of the virus can be a promis-
ing strategy for antiviral development. The results of this
study revealed that EBNs could affect the early endo-
somes and trafficking of these vesicles through manipu-
lation of actin filaments. This can be demonstrated by
the decrement of RhoA as the regulator of the actin
polymerization, and remodeling the actin filaments after
the treatment (Figs. 3 and 4). In addition, it has been
showed that decreased of Rab5 could efficiently reduce
the influenza infection [29]. Actin filaments also showed
an important role in trafficking of the initial viral par-
ticles in polarized epithelial cells [30]. Previous stud-
ies have shown that inhibition of actin filament
Fig. 5 Increase of lysosomal activity in infected MDCK cells after treatment with EBNs detected by lysoTracker Red staining. EBN1: EBN from Teluk
Intan with no enzymatic treatment, EBN2: EBN from Teluk Intan with Pancreatin F treatment, EBN3: EBN from Gua Madai with no enzymatic treatment,
EBN4: EBN from Gua Madai with neuraminidase treatment, Ama: Amantadine hydrochloride, Ose: Oseltamivir carboxylate, PR: influenza A
virus, A/Puerto Rico/8/1934 (H1N1). Images are the representatives of three replications for each treatment at 100 X oil immersion
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polymerization by cytochalasin D treatment decreased
the viral entry to the apical phase of polarized epithe-
lial cells [31]. However, this inhibitor was not effect-
ive in non-polarized cells or entering the virus from
the basolateral phase of the polarized epithelial cells.
Hence, although the amount of viral entry can be
interrupted by manipulation of the actin filaments,
the viral infectivity may not be affected by this mech-
anism [30, 31].
Despite the effects of EBNs on Rab5, RhoA and actin
filaments, this study showed that pre treatment and co
treatment of influenza virus with EBNs is not effective in
reducing viral load. This result suggests that EBNs do
not have efficient activity in inhibiting the initial stages
of viral entry probably due to the high concentration of
epidermal growth factor (EGF) in EBNs [17]. Previous
study has shown that the attachment and internalization
of the IAV can be promoted by the activation of EGF re-
ceptors [32]. Hence, in contrast to bioactivity of EBN in
decreasing the Rab5 and alteration of actin cytoskeleton,
a metabolite-like EGF can facilitate the entrance of the
virus. This effect may have been emphasized by enzym-
atic treatment of EBN since pancreatin F treatment of
the EBN (EBN2) lead to augmentation of Rab5 com-
pared to the negative control. Hence, additional studies
are required to determine the bioactive compounds of
the EBN against Rab5 protein and study the effects of
EBN on initial stages of influenza life cycle with control
of the content EGF.
Regarding the autophagy mechanism, EBN could effi-
ciently decrease the LC3-II protein and increase the
lysosomal degradation. LC3 is a protein that distributed
throughout the cytoplasm. However, after cleavage and
conjugation with phosphatidyl ethanolamine, it will be
localized on the surface of autophagosomes until the fu-
sion with lysosomes [33]. Hence, LC3-II level can be a
good marker for monitoring of autophagosomes accu-
mulation [34]. Previous study has shown that inhibition
of lysosomal proteases increased the LC3-II level during
influenza infection [35]. Thus, it can be concluded that
the effect of EBN is through increase of lysosomal deg-
radation and decrease of autophagosomes accumulation.
In this way, the intracellular accumulated viruses can be
degraded efficiently. During the influenza life cycle, au-
tophagy serves as an anabolic pool for virus assembly
and this virus triggers accumulation of autophagosomes
through M2, HA, and NS1 proteins [36]. Previous study
has shown that the inhibition of autophagy would de-
crease the influenza virus titer [37]. However, this kind
of inhibition does not affect the replication of a highly
pathogenic strain like H5N1 and only slightly ameliorate
the disease [38]. Further studies are required to evaluate
the efficacy of EBN against H5N1 and the autophagy
mechanisms against this virus.
Conclusions
Traditional medications and different natural products
have been of interest to be used for antiviral treatments.
Hence, these days a considerable amount of study is un-
derway on the potential benefit of EBN as therapeutic
agent. Although, some EBN extracts showed SI less than
10, other different ingredients in the EBN extracts my
give different ways of antiviral activity. Thus, we cannot
ignore the other EBNs simply just because of low SI.
The results procured in this study support the potential
of EBNs as supplementary medication or alternative to
antiviral agents to inhibit influenza infections. Evidently,
EBNs can be a promising antiviral agent; however,
these natural compounds should be screened for their
metabolites. For the first time, this study showed that
EBNs can inhibit the autophagy process during influ-
enza virus life cycle, which can efficiently result in
decrease in viral replication.
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